Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Klausner, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klausner, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology Pages 459-460

News from the NCI
Breast Cancer Prevention Trial
NCI Statement on Animal Studies of Endostatin and Angiostatin
News from the NCI

News from the NCI

BREAST CANCER PREVENTION TRIAL

Department of Health & Human Services, National Institutes of Health

Statement of Richard D. Klausner, M.D., Director, National Cancer Institute Before the Senate Appropriations Subcommittee on Labor, Health, Human Services and Related Agencies

April 21, 1998

Good afternoon, Senator Specter and members of the Subcommittee. I am Richard Klausner, Director of the National Cancer Institute (NCI). I am pleased to testify before you today on a remarkable advance in cancer prevention.

The goal of preventing cancer has long been a hope and a central focus of the National Cancer Program. Prevention can take many forms, from smoking cessation and other behavioral changes to vaccines or antimicrobial agents against cancer-causing infections to a new field in which medicines specifically interfere with the biologic processes of cancer development. For the past . . . [Full Text of this Article]

NCI STATMENT ON ANIMAL STUDIES OF ENDOSTATIN AND ANGIOSTATIN


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?